This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
5 Stocks With Solid Sales Growth to Keep an Eye on Right Now
by Swayta Shah
Sustained sales growth is one of the most important characteristics of potential winners in the stock market. It provides investors an insight into product demand and pricing power.
The Zacks Analyst Blog Highlights: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard and Bristol-Myers Squibb
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard and Bristol-Myers Squibb
Biotech ETFs in Focus on Impressive Q3 Earnings Results
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q3 earnings results recently.
Value Biotech ETFs & Stocks to Buy Now
by Sanghamitra Saha
Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.
The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo
The Extreme Risks of Trading Your Own Retirement Assets - November 04, 2019
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
5 High-Flying Stocks Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates
by Kinjel Shah
Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results.
Company News for Nov 1, 2019
by Zacks Equity Research
Companies in the news are: SBUX, KHC, TWTR, BMY
Simple Secrets Anyone Can Use to Reach Early Retirement - November 01, 2019
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Bristol-Myers (BMY) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Bristol-Myers (BMY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
3 Reasons Growth Investors Will Love Bristol-Myers (BMY)
by Zacks Equity Research
Bristol-Myers (BMY) possesses solid growth attributes, which could help it handily outperform the market.
Celgene (CELG) Q3 Earnings Beat, Otezla, Revlimid Sales Rise
by Zacks Equity Research
Celgene (CELG) beats on earnings and revenues in the third quarter of 2019 on strong performance from Otezla and Revlimid.
Infinity (INFI) Q3 Loss Wider Than Expected, IPI-549 in Focus
by Zacks Equity Research
Infinity's (INFI) wider-than-estimated loss in Q3 displeases investors. Revenues too fall short of the mark.
Bristol-Myers' (BMY) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Bristol-Myers (BMY) beats both earnings and sales estimates in the third quarter, primarily on robust sales of Eliquis and Sprycel.
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge
Claims, Income, Spending & Q3 Earnings: A Full Plate
by Mark Vickery
More economic morsels in today's pre-market activity, along with a continued deluge of new quarterly earnings reports, continue one of the busiest weeks for Q3 earnings season.
BMY or AZN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BMY vs. AZN: Which Stock Is the Better Value Option?
Is Bristol-Myers Squibb (BMY) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
All You Need to Know About Bristol-Myers (BMY) Rating Upgrade to Buy
by Zacks Equity Research
Bristol-Myers (BMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bristol-Myers Squibb (BMY) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Bristol-Myers (BMY) delivered earnings and revenue surprises of 10.38% and 3.54%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Amgen (AMGN) Beats on Q3 Earnings, Ends Neuroscience R&D
by Zacks Equity Research
Amgen (AMGN) posts encouraging third-quarter 2019 results. It raises its previously issued sales guidance slightly while increasing the earnings range significantly.
Should You Buy Bristol-Myers (BMY) Ahead of Earnings?
by Zacks Equity Research
Bristol-Myers (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q3 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Opdivo and Eliquis along with updates on the Celgene merger, when Bristol-Myers (BMY) reports third-quarter results.
Factors Setting the Tone for Bristol-Myers (BMY) Q3 Earnings
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with updates on the Celgene merger, when Bristol-Myers (BMY) reports third-quarter results.